Seeking Alpha

Avanir Pharmaceuticals inks co-promotion deal with Merck on Januvia

  • Avanir Pharmaceuticals (AVNR) ramps higher in the post-session after saying it's entered into an exclusive, multi-year agreement with Merck (MRK) to co-promote MRK's type 2 diabetes therapies Januvia and the sitagliptin family of products in the U.S.
  • Terms of the deal were not disclosed.
  • Shares +9.6% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs